Immunocore announces R&D leadership evolution

Core Insights - Immunocore Holdings plc announces the departure of Dr. David Berman, Executive Vice President of Research and Development, effective February 27, 2026, as he takes a new role at another biotech company [1] - The company will not seek a direct replacement for Dr. Berman but will streamline its R&D structure, promoting Dr. Mohammed Dar and Mark Moyer to Executive Vice President roles [2] Leadership Changes - Dr. Mohammed Dar, previously Chief Medical Officer, has extensive experience in leading clinical development and will now oversee expanded clinical development and regulatory strategies [4] - Mark Moyer, who has been with Immunocore since 2018, will become EVP, Chief Regulatory and Quality Officer, having led the regulatory strategy for KIMMTRAK, which is now approved in 39 countries [5] Company Overview - Immunocore is a commercial-stage biotechnology company focused on developing TCR bispecific immunotherapies, particularly its lead product KIMMTRAK, which treats HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma [6]